In einer Phase I/II Studie wurde die tolerable Dosierung und antileukämische Wirksamkeit der Kombination von AMSA und Etoposid (VP 16-213) bei 20 Patienten mit refraktärer akuter myeloischer Leukämie untersucht. Dabeí erwies sich ein 5tägiger Therapiezyklus als tolerabel und wirksam: AMSA 210 mg/m2/die an den Tagen 2, 3, 4 und Etoposid an den Tagen 1 und 5 in fraktionierter Applikation von 100 mg/m2 über 1 h, gefolgt von einer 23stündigen Dauerinfusion von 230 mg/m2. 5 von 20 Patienten erreichten eine partielle Remission; 4 dieser Patienten waren primär resistent gegen zwei TAD Induktionskurse. 7 der 8 Patienten mit primärer TAD Refrakterität kamen in eine Knochenmarkaplasie ohne residuale Blastenpopulation. AMSA/Etoposid scheint daher eine antileukämische Effektivität ohne Kreuzresistenz gegen TAD zu besitzen.

Keywords:
Therapierefraktäre AML, AMSA, Etoposid
This content is only available via PDF.
© 1985 S. Karger AG, Basel
1985
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.